Cases of Breast Implant-Associated Lymphoma Continue to Accumulate More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge Mar 06, 2023
'Our Goal Is Not to Omit Radiation Therapy' in Breast Cancer Honing indications for de-escalation of treatment intensity and, yes, selective omission of RT Mar 06, 2023
Antibody-Drug Conjugates Take Breast Cancer Field by Storm Established role in metastatic disease, may eventually replace chemotherapy Mar 04, 2023
These Surgeries Made the Sharpest Turns to Outpatient Setting After COVID Several procedures saw significant increases in outpatient volumes Mar 03, 2023
How to Make Meaningful Moves Toward Health Equity in Cancer Care Addressing the three R's: resources, research, and racism Feb 27, 2023
Safe to Omit RT After Lumpectomy in Certain Older Breast Cancer Patients Radiotherapy reduced local recurrence, but showed no effect on OS, distant recurrence Feb 15, 2023
FDA Greenlights First Drug for ESR1-Mutated Breast Cancer Elacestrant almost doubled PFS versus standard endocrine therapy in advanced ER+/HER2- disease Jan 30, 2023
MRI-Guided Focused Ultrasound Eases Pain From Bone Metastases More responses with ultrasound, but quality-of-life scores lower vs EBRT in nonrandomized trial Jan 11, 2023
Genomic Assay May Pinpoint Who Can Skip RT After Breast-Conserving Surgery Patients categorized as low risk with 16-gene signature showed no significant benefit with RT Jan 06, 2023
Optimizing Treatment for Older Patients With HR+ Low-Risk Breast Cancer Five days of radiotherapy, five years of hormonal therapy, or somewhere in between? Jan 05, 2023
Mixed Results With Hormonal Strategies for Premenopausal Breast Cancer Exemestane reduced recurrence, metastasis versus tamoxifen, but no survival benefit Dec 20, 2022
Less Is More Wins Again: Avoiding Node Dissection in Early Breast Cancer First comparison of targeted sentinel node assessment shows no difference in recurrence rates Dec 09, 2022
Adding AKT Inhibitor Doubles PFS in Advanced, HR-Positive Breast Cancer In phase III trial, capivasertib benefited patients with or without AKT pathway alterations Dec 09, 2022
Oral SERD Tops Fulvestrant for PFS in ER-Positive Breast Cancer Camizestrant also led to meaningful PFS improvements in those with detectable ESR1 mutations Dec 09, 2022
Continuing CDK4/6 Inhibitor Beyond Progression No Help in Metastatic Breast Cancer Prior therapy, baseline mutations confound results; "intriguing" benefit with PD-L1 inhibitor Dec 09, 2022
Pausing Endocrine Therapy for Pregnancy Safe in Early Breast Cancer Study suggests no increased risk of cancer recurrence versus historical control Dec 09, 2022
T-DXd Continues Winning Streak in Metastatic, HER2-Positive Breast Cancer Trastuzumab deruxtecan improves survival in second- and later-line settings Dec 08, 2022
Neoadjuvant T-DXd Active in HER2-Low Breast Cancer Response rates on the order of 58-68%, with or without endocrine therapy Dec 08, 2022
Everolimus Fails Again as Adjuvant Therapy for High-Risk Breast Cancer No improvement in the overall analysis but a hint of benefit in premenopausal patients Dec 08, 2022
Assay Predicts Breast Cancer Patients Who Will Benefit From Ovarian Suppression Low score suggests improved outcomes with ovarian suppression plus adjuvant endocrine therapy Dec 07, 2022
First-Line CDK4/6 Thumps Chemo in Aggressive, Advanced Breast Cancer Doubling of PFS could be death knell for combination chemotherapy in difficult-to-treat subgroup Dec 07, 2022
Metastasis 'Doorway' May Lead to Racial Disparities in Breast Cancer Density of cellular complex after neoadjuvant therapy tied to cancer subtypes, may be targetable Dec 07, 2022
Exercise During Chemo Shows Benefits for Cardiorespiratory Fitness However, patients who exercise after chemo also ultimately see benefits too Nov 21, 2022
RT After Breast-Conserving Surgery Shows No Survival Advantage Decades Later But "that's not the intent of radiation therapy," says outside expert Nov 18, 2022
Oral, Hormone-Free Med Reduces Hot Flashes in Breast Cancer Patients Q-122 was effective, well-tolerated in those on oral adjuvant endocrine therapy Nov 11, 2022
My Risk Revealed: A Confirmed BRCA2 Mutation My dad's cancer diagnosis offered me invaluable information Oct 30, 2022
Study Suggests Potential to Skip Surgery for Selected Breast Cancer Patients No recurrences in 2 years after pathologic complete response in TNBC, HER2-positive tumors Oct 26, 2022
Concurrent Boost During Hypofractionated RT Proves Its Worth in Early Breast Cancer Reduces treatment time, noninferior to conventional RT with sequential boost after lumpectomy Oct 26, 2022
Nerve-Freezing Technique Staves Off Post-Mastectomy Pain Percutaneous cryoneurolysis improved analgesia in a pilot study Oct 24, 2022
Mepitel Film Beats Standard for Stopping Radiation Dermatitis in Breast Cancer "The most improvement in skin toxicity that I have seen in many years," expert says Oct 19, 2022
Risk of Secondary Breast Cancer After Childhood Cancer Is Declining, Study Suggests Improvement credited to changes in chest RT, attenuated by use of pelvic RT, anthracyclines Oct 13, 2022
This One Risk Factor Dominates for Soft Tissue Sarcoma After Breast Cancer Risk is low but appears to have modifiable components Oct 13, 2022
Katie Couric's Breast Cancer The popular media personality is on a mission to raise awareness around dense breasts Oct 06, 2022
Hand Cooling, Compression Both Effective for Nerve Pain in Breast Cancer But access, cost, and tolerability may favor the latter option, said researcher Sep 14, 2022
Denosumab Halts Bone Loss From Ovarian Suppression, AIs for Breast Cancer Areal BMD increased when given at the start of maximal estradiol depletion therapy Sep 13, 2022
Targeted Combo Flops as First-Line Treatment in Advanced Breast Cancer No clinical benefit boost with anti-CD73 oleclumab added to durvalumab and chemo Sep 10, 2022
Antibody-Drug Conjugate Prolongs Survival in Metastatic Breast Cancer Positive outcome with sacituzumab govitecan leads to questions about ADC sequencing Sep 09, 2022
2 Years of Endocrine Therapy, 2 Decades of Protection From Metastatic Breast Cancer Tamoxifen protects low-risk premenopausal patients, goserelin helps high-risk patients Aug 31, 2022
Do Therapy-Related Hot Flashes in Breast Cancer Signal Worse Outcomes? Swedish study finds reduced DFS in women who used drugs for hot flashes Jun 22, 2022
Diabetes Threatens Long-Term Survival in Metastatic Breast Cancer 5-year survival rates were not affected, however Jun 13, 2022
